GlassScriptPhysician profile
Pablo D Dayer
NPI 1972778165
$2,844.15
in general payments reported to CMS, 2019-2025
33 companies · $1,160 in 2025
The $1,160 reported for 2025 was more than what 81% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $446 · 2020: $162 · 2021: $92.45 · 2022: $246 · 2023: $330 · 2024: $409 · 2025: $1,160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,892 · Education: $6.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,891.60 |
| Education | $6.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $503.84 | 2019-2025 | Krystexxa, Tavneos |
| Akebia Therapeutics INC | $343.93 | 2019-2025 | Vafseo |
| Astrazeneca Pharmaceuticals LP | $315.42 | 2019-2025 | Farxiga, Lokelma, Saphnelo |
| Travere Therapeutics, INC. | $208.64 | 2019-2025 | |
| Vantive US Healthcare LLC | $173.96 | 2025 | Renal - Acute, Renal - Pd |
| Glaxosmithkline, LLC. | $152.16 | 2022-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $106.83 | 2019-2025 | |
| Mallinckrodt Enterprises LLC | $106.60 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $97.08 | 2019-2025 | Jynarque |
| Viiv Healthcare Company | $95.12 | 2024-2025 | Rukobia, Cabenuva, Dovato |
| Calliditas Therapeutics US INC. | $88.57 | 2022-2025 | Tarpeyo |
| Horizon Therapeutics Plc | $84.38 | 2021-2023 | Krystexxa |
| Scpharmaceuticals INC. | $83.17 | 2024-2025 | |
| Theratechnologies INC. | $50.26 | 2025 | Trogarzo, Egrifta |
| Pharmacosmos Therapeutics INC. | $50.24 | 2025 | Monoferric |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $43.50 | 2024-2025 | Bimzelx |
| Apellis Pharmaceuticals, INC. | $38.04 | 2025 | Empaveli |
| Radius Health, INC. | $27.76 | 2025 | |
| Janssen Biotech, INC. | $26.48 | 2019 | |
| Allergan, INC. | $25.96 | 2019 | |
| Vifor Pharma, INC. | $25.72 | 2025 | Veltassa |
| Paratek Pharmaceuticals, INC. | $24.86 | 2024 | Nuzyra |
| Merck Sharp & Dohme LLC | $23.10 | 2025 | Pifeltro |
| Bayer Healthcare Pharmaceuticals INC. | $23.02 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.32 | 2025 | Jardiance |
| Fresenius USA Marketing, INC. | $15.25 | 2022 | |
| Alexion Pharmaceuticals, INC. | $15.17 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $14.67 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $14.51 | 2020 | |
| Lilly USA, LLC | $13.41 | 2021 | |
| Emd Serono, INC. | $13.23 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $12.88 | 2023 | Vibativ |
| Biomerieux INC | $10.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pablo Dayer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.